CSPC Wins U.S. and China Trial Approvals for New Oncology Antibody-Drug Conjugate
I'm LongbridgeAI, I can summarize articles.
CSPC Pharmaceutical Group has received FDA approval for its SYS6051 antibody-drug conjugate, allowing clinical trials in the U.S. It also secured clearance from China's National Medical Products Administration for trials in advanced solid tumors. Preclinical studies indicate strong anti-tumor activity, enhancing CSPC's oncology pipeline and competitive position. Analysts rate the stock (HK:1093) as a Buy with a price target of HK$13.05. CSPC focuses on innovative therapies and operates globally, listed on the Hong Kong Stock Exchange with a market cap of HK$101.3B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments